Search Results
Data for ibrutinib in CLL: RESONATE - Gomez
Data for ibrutinib in CLL: RESONATE-2 and HELIOS - Coutre
Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL
Upfront Ibrutinib: RESONATE-2 Trial
Abstract: Single-agent Ibrutinib 420mg Induces Durable Responses in Patients with CLL
Impressive results from phase 3 RESONATE trial in CLL
Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL
Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design
Approaches to the fit (go-go) patient in Latin America - Gomez
Outcomes from the RESONATE 2 and HELIOS Trials—Clinical Impact
Management of CLL in 2021 and Beyond
